Attempts to treat patients using approved anti-IL-1 and IL-6 have been somewhat successful in ARDS (Shakoory et al., 2016; Toniati et al., 2020), albeit there are concerns with consequent risks of immunosuppression using currently available anti-IL-1 and anti-IL-6 (respectively, Kineret and Tocilizumab (Felsenstein et al., 2020; Zhang et al., 2020). The gene discussed is IL1B; the disease is acute respiratory distress syndrome.